Karin Jooss
Chief Tech/Sci/R&D Officer presso GRITSTONE BIO, INC.
Patrimonio netto: 1 M $ in data 31/03/2024
Profilo
Karin Jooss is an Independent Director at Fate Therapeutics, Inc. since 2019.
She is also the Executive VP & Head of Research & Development at Gritstone bio, Inc. since 2021.
Previously, she worked as the Vice President of Research at Cell Genesys, Inc. from 2005 to 2009 and as the Head of Cancer Immunotherapeutics at Pfizer Inc. from 2009 to 2016.
Dr. Jooss holds a doctorate degree from Philipps University of Marburg.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
GRITSTONE BIO, INC.
0.40% | 01/02/2024 | 395 204 ( 0.40% ) | 1 M $ | 31/03/2024 |
FATE THERAPEUTICS, INC.
0.01% | 06/06/2023 | 9 848 ( 0.01% ) | 72 284 $ | 31/03/2024 |
Posizioni attive di Karin Jooss
| Società | Posizione | Inizio |
|---|---|---|
| GRITSTONE BIO, INC. | Chief Tech/Sci/R&D Officer | 13/04/2016 |
| FATE THERAPEUTICS, INC. | Director/Board Member | 14/03/2019 |
Precedenti posizioni note di Karin Jooss
| Società | Posizione | Fine |
|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | 01/04/2016 |
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Chief Tech/Sci/R&D Officer | 01/04/2009 |
Formazione di Karin Jooss
| Philipps University of Marburg | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| PFIZER, INC. | Health Technology |
| FATE THERAPEUTICS, INC. | Health Technology |
| GRITSTONE BIO, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Health Technology |
- Borsa valori
- Insiders
- Karin Jooss
